Pfizer, BioNTech To Seek FDA Approval For Booster Shots For 16 And 17-year Olds- Reports

Drug major Pfizer Inc (PFE) and German partner BioNTech SE (BNTX) are likely to seek approval from the U.S. Food and Drug Administration for their COVID-19 vaccine booster shot for 16 and 17-year olds, the Washington Post reported citing people familiar with the matter.

The companies are expected this week to apply for the regulatory approval. If approved, it would be the first booster available to people in this age group.

The development comes amid the fear of the new Omicron variant, which was first detected in South Africa and spreads to other countries. Meanwhile, the new variant is yet to be detected in the United States.

Pfizer and other major covid vaccine makers are investigating Omicron, the new, heavily mutated coronavirus variant, and are said to be working to adapt their vaccines, if needed.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Home improvement company Lowe's and pet retailer Petco Health and Wellness Co. are set to launch a pilot store-in-store program whereby a total home solution will be offered to customers by bringing home improvement as well as pet care products, services and expertise together under the same roof. Chevron Corporation (CVX) reported fourth quarter profit of $5.1 billion or $2.63 per share, compared to a loss of $665 million or $0.33 per share, previous year. The company's U.S. upstream operations earned $2.97 billion, compared to $101 million, a year ago. The company said the improvement was primarily... While reporting financial results for the fourth quarter on Friday, Colgate-Palmolive Co. (CL) initiated its earnings and sales growth guidance for the full-year 2022. For fiscal 2022, the company now expects earnings per share to grow in double-digit percentage and adjusted earnings per share growth...
Follow RTT